Article
Fracture healing with alendronate treatment in the Brtl/+ mouse model of osteogenesis imperfecta.
Bone - 1 Sept 2013
Meganck J A, Begun D L, McElderry J D, Swick A, Kozloff K M, Goldstein S A, Morris M D, Marini J C, Caird M S
Abstract excerpt
Osteogenesis imperfecta (OI) is a heritable bone dysplasia characterized by increased skeletal fragility. Patients are often treated with bisphosphonates to attempt to reduce fracture risk. However, bisphosphonates reside in the skeleton for many years and long-term administration may impact bone material quality. Acutely, there is concern about risk of non-union of fractures that occur near the time of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
